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ABSTRACT 
 
 
 
 The main source of morbidity and mortality in cancer is the metastasis of cancer once it 
has developed.  4-methylthio-2-oxobutyric acid (MTOB) is a drug shown to be effective in 
inducing apoptosis in cancer cells regardless of the presence of active p53 tumor suppressor, due 
to its interaction with CtBP transcription repressor. The purpose of this MQP was to determine 
whether MTOB is an effective treatment for reducing cancer cell migration. This was done using 
wound healing assays to characterize cancer cell migration in the presence or absence of MTOB.  
The results show that the migration of U2OS, HCT116 -/-, and MCF7 cancer cells was reduced 
by 10 mM MTOB treatment. 
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BACKGROUND 
 
 
Cancer Metastasis 
 It is widely known that cancer cells migrate and can metastasize to areas of the human 
body that differ from where they originated. This metastasis is caused by two main factors: 1) the 
migration of cells that spread locally, and 2) the detachment of cells that are then released into 
the bloodstream or lymphatic system that spread systemically. Cells that spread via the 
circulatory system can localize in other major body systems and cause serious complications for 
cancer patients (Sadanandam, et al., 2010).  Thus, research into cancer cell migration, and 
treatments for it, are crucial. 
 
Cell Migration 
 The spread of cancer cells through metastasis is highly dependent on cell motility. 
Without the inherent ability of the cells to migrate, the cells remain in one place only, and grow 
without spreading (Gupta et al., 2005).  Of all the mechanisms that induce cells to migrate, the 
activity of the corepressor C-terminal Binding Protein-2 (CtBP2) (discussed below) is critical, in 
both p53-dependent and p53-independent cancer lines, due in part to its transcriptional regulation 
of genes related to proliferation, invasion, and metastasis, and due to its interaction with 
adhesion proteins such as PTEN and E-Cadherin (Zhang et al., 2006). 
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C-Terminal Binding Proteins 
 CtBP is a protein that stimulates tumor cell migration.  It localizes mainly to the nucleus, 
and is well known to act as an active repressor and corepressor of the transcription of genes, 
many of which inhibit the proliferation, invasion, and metastasis of cancer (Chinnadurai, 2009). 
The genes repressed by CtBP can be grouped largely by their main effects on cell growth and 
motility.  
 The first group of genes targeted by CtBP control cellular proliferation. The genes mainly 
included in this are the cell cycle inhibitors p16
INK4a
 and p15
INK4b
, two genes that directly affect 
the proliferation of cells by causing G-1 phase cell cycle arrest (Scaini et al., 2009). CtBP 
represses the expression of p16 and p15, thus increasing mitosis. 
    Another cellular proliferation gene targeted by CtBP is the phosphatase and tensin 
homolog (PTEN) (Chinnadurai, 2009).  PTEN acts as a tumor suppressor through its interaction 
and inhibition of the AKT pathway.  The AKT pathway is a powerful source of cellular 
proliferation through activation of the cell cycle and growth (Tamura et al., 1999).  CtBP inhibits 
PTEN transcription, thereby increasing the AKT pathway and tumor proliferation. 
 In addition to inhibiting genes which cause cell cycle arrest and thus increasing cellular 
proliferation, CtBP also represses many genes that inhibit cellular migration. One gene affected 
is the aforementioned PTEN which has been shown to cause increased cellular migration, in this 
case CtBP represses PTEN to increase cellular migration (Bowen et al., 2009). Along with the 
repression of PTEN, another target of CtBP repression is the E-Cadherin, a powerful cellular 
adhesion protein, that when repressed increases cell mobility (Zhang et al., 2006). 
 A final way in which CtBP acts to increase oncogenesis is through its interactions with 
many genes that would normally trigger apoptosis, thus increasing cell survival. This is shown 
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through its repression of such powerful apoptosis-inducing genes as PERP, Bax, and NOXA. By 
inhibiting these genes directly, as well as through its interaction with mdm2 causing repression 
of p53, CtBP is a strong cause of the survival of cells that would under normal circumstances 
undergo apoptosis (Chinnadurai, 2009).  A summary of the role of CtBP in oncogenesis is shown 
in Figure-1, and the protein remains under continuous research. 
 
Figure-1: Interaction of CtBP with Common Tumor Suppressors.  Shown above is 
the repressor activity of CtBP upon tumor suppressors such as p15
INK41
, p16
INK4b
 and 
PTEN, causing increased cellular proliferation.  In addition to this it is known that CtBP 
represses E-Cadherin and PTEN which causes increased cell mobility. And finally it is 
shown that CtBP upregulates MDM2, a suppressor of p53; CtBP also represses PERP, 
Bax, and NOXA, targets for upregulation by p53.   
 
MTOB 
 In the Grossman Lab at Umass Medical School (Worcester), in the search for active 
repressors of CtBP for use as cancer therapeutics it was found that ARF, a product of the PTEN 
gene, targets CtBP for nuclear localization and proteasome degradation (Paliwal et al., 2006). 
During the course of these investigations it was also found that the compound MTOB, the 
penultimate compound in the methionine salvage pathway, is able to bind to CtBP and repress its 
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activity (Straza et al., submitted).  Alone, MTOB in large doses is able to cause significant 
apoptosis in vitro, and has been shown to be an effective tool for reducing the survivability of 
cancer cells (Tang et al., 2006). Ongoing research in the Grossman Lab shows that MTOB is 
both a safe and effective treatment in vivo for reducing the size and spread of tumors. With this 
in mind, this MQP was performed to determine the effectiveness of MTOB against cancer cell 
migration. 
 
Cancer Cell Lines 
 To show MTOB’s effectiveness in a large range of cancer types, multiple cancer lines 
were studied in this project. The first of these was the osteosarcoma cell line U2OS. 
U2OS cells are known to be an invasive line of osteosarcoma cells showing a large amount of 
cellular migration when plated (Cho et al., 2007). This line of cells is used primarily as a model 
for human bone cancers. These cells are positive for the tumor suppressor p53, a powerful 
regulator of cell cycle arrest and apoptosis. U2OS cells were originally isolated from a 
differentiated sarcoma from the tibia of a 15 year old girl in 1964 (U2OS Product Description, 
2009).  
 The next line of cells used in these experiments was the MCF7 cell line.  The MCF7 line 
of breast adenocarcinoma was used to support the p53 positive data of the U2OS cell line. MCF7 
cells are a metastatic cancer line that is both p53 positive and shows a significant amount of cell 
migration (Khanfar et al., 2009).  This cell line was isolated from an adenocarcinoma in a pleural 
effusion of a 69 year old female (MCF7 Product Description, 2009).  
 The third cell line used in this MQP was the HCT116 -/- cell line.  p53 is one of the most 
important suppressors, and inactivated by mutation or by alteration in its pathway in almost 50% 
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of all human cancers (Zilfou & Lowe, 2009).  The HCT116 -/- cell line has a point mutation 
causing the cancer line to be p53 negative. Without p53, many of the common chemotherapy 
drugs that stimulate p53 activity are ineffective.  These HCT116 cells were isolated from an 
adult male colorectal carcinoma (HCT116 Product Description, 2009).  Each of these cell lines is 
known to actively metastasize through the migration of the cells. 
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PROJECT PURPOSE 
 
 The Background section shows that cancer cell metastasis is an important issue in 
designing drugs to block tumors.  C-terminal Binding Protein (CtBP) is a protein previously 
shown to increase tumor cell division, migration, and survival.  MTOB is a known inhibitor of 
CtBP.  This MQP project is directed to show that MTOB is an effective treatment for both killing 
cancer cells and stopping cancer cell metastasis. The hypothesis tested in this MQP is that cancer 
cell migration is drastically reduced after treatment with MTOB.  Three cell lines (U2OS, 
HCT116 -/-, and MCF7) will be plated on 6-well plates. In each well, three scratches will be 
made to create space into which the cells can migrate, and the cells will then be photographed 
over time through a microscope. Three wells will be treated with 10 mM NaCl as a control and 
another three wells will be treated with 10 mM MTOB.  After 8 or 16 hours, the wells will be 
photographed again to show the difference in scratch size. This will be used to confirm the 
hypothesis that the cells treated with MTOB will migrate less than the cells treated with the NaCl 
control. 
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METHODS 
 
 
Cell Culture 
Cell Lines 
 The cell lines used during these experiments were U2OS, HCT116-/-, and MCF7. The 
U2OS cells were provided by Seema Paliwal, and the HCT116 -/- and MCF7 cells were provided 
by Mike Straza. The U2OS cells are an osteosarcoma line that is p53 positive. The HCT116 -/- 
cells are a line of human colorectal carcinoma cells that are mutated with a point mutation in 
p53. The MCF7 cells are a line of breast cancer cells that are also p53 positive. 
 
Cell Media 
 The U2OS cells were cultured on T75 flasks using DMEM High Glucose media 
supplemented with 10% FBS and 1% Pen-Strep.  The HCT116 -/- cells were cultured in T25 
flasks using McCoy’s Media supplemented with 10% FBS and 1% Pen-Strep.  The MCF7 Cells 
were cultured in T25 flasks using DMEM Low Glucose media supplemented with 10% FBS and 
1% Pen-Strep. 
 
Cell Splitting 
 Each cell line was split by first washing with PBS, and then trypsin with EDTA was used 
to remove the adherent cells from each plate. Media was then added and the cells were then 
centrifuged at 2000 rpm for 5 minutes. Cells were then plated at the desired dilution into the 
same or additional flasks. 
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Wound Healing Assays 
Cell Plating 
 Cells were plated on 6-well plates and run in triplicate. Three wells represented negative 
controls using NaCl-supplemented media at 10 mM, while three wells of 10 mM MTOB-treated 
cells represented the experimental group.  Each well had a series of three scratches made using a 
sterile P1-200 micropipette tip. These scratches were then photographed using a microscope to 
provide a baseline size for each “wound”.  After 8 or 16 hours, the media was aspirated off the 
plates, and each wound was photographed in 15 unique places to display the “wound” size after 
the specified time had passed. The arrangement of wells for each of the wound healing assays is 
shown in Figure-2. 
 
Figure-2:  Diagram of the 6-Well Plate Organization  
for a Wound Healing Assay. 
 
Treatment with MTOB 
 A 40 mM stock of MTOB was created in each of the media used for each cell line. This 
was done by adding 62 mg of MTOB to 10 mL of each medium. In addition to this, the control 
stock was created for each media by adding 23 mg of NaCl to 10 mL of each medium. The 
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resulting concentrated solution was stored in 15mL falcon tubes, and kept at 4
o
C until use. The 
media was then diluted 1:4 for a final concentration of 10 mM in each well. 
Data Analysis 
 Each photograph was imported to Adobe Photoshop, and measured for wound size. The 
average size of the original wound was then compared with the size of the wound after 
migration, and the distance moved and percent wound closure for each well was calculated and 
averaged. 
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RESULTS 
 
 
 As stated before, the purpose of this MQP was to show the reduction in cellular migration 
of three different tumor cell lines after being treated with the prospective cancer drug MTOB. A 
series of repetitive wound healing assays were conducted at the 8 hour and 16 hour time points 
for each cell line.  
 
U2OS Migration 
 The first cell line to be tested for MTOB effect was the U2OS osteosarcoma cell line. The 
raw data was collected by taking photographs of the scratches (“wounds”) in each well both 
before and after treatment. An image of a scratch in each well was taken at time zero and used to 
form a baseline size of each scratch in each of the wells. The wells were then treated with the 
NaCl control or the MTOB treatment at 10 mM, and allowed to run for 8 or 16 hours depending 
on the frame of the experiment being run. After the allotted time had passed, the medium in each 
well was removed, and the scratches photographed again, this time in 15 unique locations to 
allow correction for any size discrepancy between the final distances that each “wound” closed 
to.  These photographs were then analyzed in Adobe Photoshop to calculate the distance moved 
by the cells in each well.   
 Figure-3 shows the difference in cell migration after 16 hours in a U2OS migration 
assay.  Using Adobe Photoshop, these pictures were measured for the average distance between 
the edges, and compared between MTOB-treated (figure right side) and control images (figure 
left side).  It is clearly evident in these pictures that the MTOB treatment (D) inhibits cell 
migration into the clear zone compared to untreated cells (C). These cells showed a 43% 
reduction in migration after 8 hours, and a 55% reduction in migration after 16 hours, normalized 
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to the NaCl treated control cells (Figure-4). The raw unprocessed data can be found in the 
Appendix at the end of the report. 
 
 
Figure-3. Measurement of U2OS Cellular Migration at 16 Hrs.  Cells treated with 
NaCl are shown at time zero (A) and after 16 hours (C).  Also shown are cells treated 
with MTOB at time zero (B) and after 16 hours (D). 
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Figure 4. MTOB Inhibition of U2OS Tumor Cell Migration. U2OS cells were 
treated with 10 mM MTOB or 10 mM NaCl as a control, and then allowed to 
migrate for 8 hours (above) or 16 hours (below) into a scratched area on the 
microtiter well.  Each histobar denotes the mean of 12 determinations for 8 hours, 
and N=6 for 12 hours.  Error bars denote standard error. 
 
HCT116 -/- Migration 
 In addition to the U2OS tumor cell line, a p53-negative cell line was used in this MQP, 
the HCT116 -/- cell line from a human colorectal carcinoma. These cells showed a 49% 
reduction in migration after 8 hours, and a 31% reduction in migration after 16 hours, when 
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normalized to the saline-treated control (Figures 5 and 6).  Thus MTOB can reduce the 
migration of both a p53 positive and a p53 negative cancer cell line.   
 
 
  
Figure-5.  HCT116 -/- Cell Migration at 16 Hours.  HCT116 -/- cells were treated with 
NaCl at time zero (A) and after 16 hours (C).  Also shown are cells treated with MTOB at 
time zero (B) and after 16 hours (D). 
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Figure 6.  Summary of HCT116 -/- Cell Migration Results.  HCT116 -/- cells were treated with 10 
mM MTOB or 10 mM NaCl as a negative control, then allowed to migrate for 8 hours (above) or 16 
hours (below) into a scratched surface.  Each histobar denotes the mean of 6 determinations for 8 hours, 
and N=9 for 16 hours.  Error bars denote standard error. 
 
 
 
 
 
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
0.2
NaCl MTOB
Pe
rc
en
t 
M
ig
ra
ti
o
n
Migration of HCT116 -/- Cells Over 8 Hours
Percent 
Migration
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
NaCl MTOB
P
er
ce
n
t 
M
ig
ra
ti
o
n
Migration of HCT116 -/- Cells Over 16 Hours 
Percent 
Migration
 19 
MCF7 Migration 
 The final cell line used during this MQP was the MCF7 breast adenocarcinoma. This line 
was used as an additional p53 positive cell line to show the reduction in cellular migration 
caused by MTOB. These cells are grown in a low glucose DMEM media as opposed to the high 
glucose media used for the U2OS cells. Figure-7 shows images of the MCF7 migration at 16 
hours.  The graphs in Figure-8 show that there was a 49% reduction in migration after 8 hours, 
and a 29% reduction in cellular migration after 16 hours when normalized to the saline controls. 
 
 
Figure 7. MCF7 Cell Migration After 16 Hours.  MCF7 cells treated with NaCl at time 
zero (A) and after 16 hours (C).  Also shown are cells treated with MTOB at time zero (B) 
and after 16 hours (D). 
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Figure 8. Summary of MCF7 Migration Results. MCF7 cells were treated with 10 mM 
MTOB or 10 mM NaCl as a negative control, and then allowed to migrate for 8 hours (above) 
or 16 hours (below) into a scratched surface.  Each histobar denotes the mean of 6 
determinations for 8 hours, and N=9 for 16 hours.  Error bars denote standard error. 
 
Final Analysis 
 Once all the migrations for each cell line were completed, they were compiled into 
Figure-9.  These numbers were then normalized to the NaCl control values for each repetition of 
each experiment. 
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Figure 9. Compilation of Normalized Cell Migration Results.  The results from each cell line were 
combined into a single graph (top), and then normalized to the saline control values (bottom). 
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DISCUSSION 
 
Major Conclusions 
 The hypothesis that MTOB reduces cellular migration in multiple cell lines is supported 
by the summary results in Figure 9. This figure shows a significant reduction in migration at both 
8 hours and 16 hours in the U2OS, HCT116 -/-, and MCF7 cell lines. These results support the 
initial hypothesis that MTOB reduces the migration, and thus possibly the metastasis, of cancer 
cells regardless of the presence of p53.  Thus, MTOB may be a useful therapeutic in reducing 
neoplastic invasion and migration of cancer cells.  In conjunction with this evidence supporting 
the effectiveness of MTOB in killing cancer cells independent of the presence of p53, the 
viability of MTOB as an efficient cancer treatment is very much a possibility. 
Complications 
 Despite the effectiveness of the wound healing assay as a way to estimate cell migration 
accurately, mistakes are inevitable. During the course of these experiments some of the runs had 
to be discarded and were impossible to analyze due to errors in plating or procedure. These 
errors included mistakes in the confluence at plating, causing the wells to reach confluence at 
different times; or the usage of incorrect media for each plate. 
 Some complications were unavoidable.  Most cell lines at some point of continuous 
culture reach their passage limit and die.  In this project, for the MCF7 cell line, there was a time 
at which both the working stock and frozen stock cells died.  Another complication that occurred 
was the receipt of unusable media, causing massive loss of cell lines across the board. Except for 
these complications, the experiments used in this MQP were efficient and effective in producing 
the expected results in support of the hypothesis. 
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Future Experiments 
 The future of MTOB research is focused on finding analogs that are more effective at 
lower dosages. Due to the high 10 mM dose of MTOB required, while reachable in a mouse 
model, treatment in the human body would be extremely expensive and inefficient. The prospect 
of an analog of MTOB with only minor changes that could exponentially increase its 
effectiveness is a desired goal.  In addition to the analog research, studies testing the 
effectiveness of MTOB in conjunction with other current known cancer treatments should be 
performed.  Cancer is usually treated with a combination of drugs rather than a single drug. This 
research might also lead to interest from drug companies providing their drugs that might work 
well in conjunction with MTOB. The final future experiment to be mentioned is an expansion of 
the ongoing research of the Grossman Lab with MTOB as an in vivo treatment to show its 
effectiveness and safety in an animal model. Following this research, MTOB may yet be 
developed as a safe and effective treatment for cancer, independent of p53 status of the tumor. 
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APPENDIX 
 
U2OS 8-21-09 
U2OS   Control   MTOB  
82109  C1 C2 C3 M1 M2 M3 
 1 6 6 7.75 7 6.25 5.75 
 2 6.5 6.25 7.75 7.25 6.25 5.75 
 3 6.25 6 7.25 7.25 5.75 6 
 4 6.25 6 7.5 7.5 6 5.75 
 5 6 6.25 7.25 7 6.25 5.75 
 Avg 0 6.2 6.1 7.5 7.2 6.1 5.8 
        
 1 3.5 3.25 3.75 5.25 4.5 4.25 
 2 4 3.75 4.5 5.75 4.25 4.75 
 3 4 3.5 5.5 5.25 5.25 4.25 
 4 4 3.25 5.25 6 4.25 4.75 
 5 3.75 3.5 4.75 6.25 4.75 4 
 6 4.5 3.25 5 5.75 4.5 4.5 
 7 4 4.25 4.75 5.75 4.5 4.25 
 8 3 4.25 4.25 6 4.75 4.5 
 9 3 4.5 4.75 5.75 4.75 4.75 
 10 3.75 4.75 4.5 6.25 5.5 5 
 11 4 5 4.75 6.5 4.75 4.25 
 12 4.25 4.5 3.5 6.75 5.25 4.5 
 13 4.25 4.5 4.5 6.25 5 4.5 
 14 4.5 4.75 5.25 5.75 5.25 4.75 
 15 4.25 4.5 4 6 5 4.75 
 Avg 8 3.916667 4.1 4.6 5.95 4.816667 4.516667 
        
 d moved 2.283333 2 2.9 1.25 1.283333 1.283333 
 %space 0.63172 0.672131 0.613333 0.826389 0.789617 0.778736 
 %moved 0.36828 0.327869 0.386667 0.173611 0.210383 0.221264 
 Avg %  0.360938   0.201753  
 Std dev  0.030078   0.024971  
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U2OS   Control   MTOB  
82109  C1 C2 C3 M1 M2 M3 
 1 5.5 8.5 7.25 8.5 9 6.25 
 2 6.25 9 8.5 8.75 9 7.25 
 3 6 8.75 7.25 8.5 8.5 6.5 
 4 6.25 8.5 7.5 8.5 8.5 7 
 5 6 8.25 8 8.25 8.25 6.5 
 Avg 0 6 8.6 7.7 8.5 8.65 6.7 
        
 1 5 5.25 4.5 7 7.5 5.75 
 2 4.5 6.25 4.75 7 7.5 5.25 
 3 4.25 6.25 4.5 6.75 7.75 5.5 
 4 4.5 6.75 5 7 7.25 6 
 5 4.25 7 6.25 7 7.75 5.5 
 6 4.25 7.25 6.25 7.25 8.25 5.75 
 7 4 7.5 6 7.5 8 5.75 
 8 5.25 7 6.25 6.75 7.75 6.25 
 9 5 7 6 7.25 8 6.5 
 10 4.75 7.25 6 7.25 7.25 5.75 
 11 4.75 7 5.75 7.75 6.75 6.5 
 12 4.5 5.5 6.5 7.25 6.75 6.5 
 13 4.5 5.75 6 7.75 7 6.25 
 14 5 6.5 6 7 6.5 5.5 
 15 4.5 6 5.75 7.5 6.75 5.5 
 Avg 8 4.6 6.55 5.7 7.2 7.383333 5.883333 
        
 d moved 1.4 2.05 2 1.3 1.266667 0.816667 
 %space 0.766667 0.761628 0.74026 0.847059 0.853565 0.878109 
 %moved 0.233333 0.238372 0.25974 0.152941 0.146435 0.121891 
 Avg %  0.243815   0.140422  
 Std dev  0.01402   0.016375  
  
 28 
U2OS 8-26-09 
 
U2OS 
  Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
8hr 1 9.25 8.25 8 9 8.25 8.75 
 2 9.5 8.5 8 9.25 8.5 8.75 
 3 9 8 8 9.25 8.5 9.25 
 4 9 8.25 7.75 9 8.75 8.75 
 5 9.25 7.75 8 8.75 8.5 8.5 
 Avg 0 9.2 8.15 7.95 9.05 8.5 8.8 
        
 1 6.75 6.5 6 8 7.5 7.75 
 2 7 6.5 5.5 8 7.75 8.25 
 3 6.5 6 5 8.25 7 7.25 
 4 6.5 6.5 5.5 8 7.25 7.25 
 5 6.75 6.25 5.75 8.5 7.25 7 
 6 6.5 6.25 6 8.5 7.25 7 
 7 6.25 5.75 5.5 8.25 7.5 7.75 
 8 6.75 5.5 6 8.25 7 7.5 
 9 7 5.5 5.75 8 7.25 7.75 
 10 7 6 6 7.75 7.25 7.5 
 11 6.75 6 5.75 7.75 7 6.75 
 12 7.25 6 5.5 8 7 8 
 13 7 6.25 5.75 7.75 7 7.25 
 14 6.75 6 5.5 7.75 7.25 7.75 
 15 7.25 5.5 5.25 8 7 7 
 Avg 8 6.8 6.033333 5.65 8.05 7.216667 7.45 
        
 d moved 2.4 2.116667 2.3 1 1.283333 1.35 
 %space 0.73913 0.740286 0.710692 0.889503 0.84902 0.846591 
 %moved 0.26087 0.259714 0.289308 0.110497 0.15098 0.153409 
 Avg %  0.269964   0.138296  
 Tot Std dev 0.016763   0.024105  
 
  
 29 
U2OS   Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
8hr B 1 7.25 7.5 8 6.25 6.5 11 
 2 7.25 7.75 7.75 6.75 6.75 11 
 3 7.75 7.25 8 6.5 6.5 11.25 
 4 7.75 7.5 8 6.5 6.25 10.75 
 5 8 7.5 8 6 6.75 10.5 
 Avg 0 7.6 7.5 7.95 6.4 6.55 10.9 
        
 1 6 5.5 6.5 5.75 5.5 9.25 
 2 6 5.5 6.25 5.5 5.75 9.5 
 3 6.25 5 6.25 5.25 5.5 9.25 
 4 6 5.75 6.5 5.5 6 9.25 
 5 6.25 5.75 5.75 5.5 5.75 9 
 6 6.25 5.5 6.25 6 5.75 8.75 
 7 5.75 5.5 5.75 5.25 5.5 8.5 
 8 6.25 5.75 6 5.75 5.5 8.25 
 9 5.5 5.25 6.25 5.5 5.25 8 
 10 6 5.5 5.75 5.5 5.75 8 
 11 6.25 5.75 5.5 5.5 5.75 7.75 
 12 6.25 5.75 5.5 6 5.75 7.5 
 13 5.25 5.5 6 5.5 5.75 8 
 14 5.75 5.75 5.25 5.75 5.5 8.25 
 15 6 6 5.5 5.5 5.5 7.75 
 Avg 8 5.983333 5.583333 5.933333 5.583333 5.633333 8.466667 
        
 d moved 1.616667 1.916667 2.016667 0.816667 0.916667 2.433333 
 %space 0.787281 0.744444 0.746331 0.872396 0.860051 0.776758 
 %moved 0.212719 0.255556 0.253669 0.127604 0.139949 0.223242 
 Avg %  0.240648   0.163598  
 Std dev  0.024205   0.05202  
 
  
 30 
U2OS   Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
16 hr 1 9.25 9.25 9 9.25 8.25 9.25 
 2 9.25 9.25 9.25 9 8.75 9.25 
 3 9.25 9 9 9 8.25 9 
 4 9.75 9 9 8.75 8.5 9 
 5 9.25 9.25 8.75 8.75 8.25 9.25 
 Avg 0 9.35 9.15 9 8.95 8.4 9.15 
        
 1 6 4.5 4 6 5.75 5.75 
 2 6.5 4.75 2.25 5.75 5 6.5 
 3 6.5 5.5 2.25 6.25 5 6.5 
 4 6.5 5.25 3 6 5.5 6.25 
 5 6.25 5.25 3.25 6 5.5 6.5 
 6 5 6 3.25 6.25 5.25 6.5 
 7 4.5 5 3.75 6.25 5 6.75 
 8 5.25 6 2.5 7 5 6.75 
 9 5.25 6.5 2.5 5.5 5 5.5 
 10 4.75 5.75 3.75 7 5.25 6.75 
 11 5.5 6.5 2.25 7.25 5.5 6 
 12 5.5 5.75 3.25 7.25 4.5 6.75 
 13 6 5 4 6.25 5 5.75 
 14 5.25 4.5 4 6.5 4.5 6.5 
 15 5 5.25 3 7 4.25 6.75 
 Avg 16 5.583333 5.433333 3.133333 6.416667 5.066667 6.366667 
        
 d moved 3.766667 3.716667 5.866667 2.533333 3.333333 2.783333 
 %space 0.597148 0.593807 0.348148 0.716946 0.603175 0.695811 
 %moved 0.402852 0.406193 0.651852 0.283054 0.396825 0.304189 
 Avg %  0.486966   0.328023  
 Std dev  0.142805   0.060515  
 
  
 31 
U2OS   Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
16hr b 1 10 9.25 5.5 7 8.5 7.25 
 2 9.25 9 5.75 7.25 8.75 7.25 
 3 9.75 9 6 7 8.75 7.25 
 4 9.75 9 5.5 7.25 8.75 7.5 
 5 9.25 8.75 6 7.25 8 7.75 
 Avg 0 9.6 9 5.75 7.15 8.55 7.4 
        
 1 3.75 4 2 6 6 6.5 
 2 3 3.5 2.25 6 6.75 6.75 
 3 3 2.75 1.25 5.75 6.25 6.5 
 4 3 3.25 2 5.75 6 5.75 
 5 2.5 3.25 1.5 5.75 7 6.5 
 6 2.25 3.75 2.25 6 6.25 6.25 
 7 1.25 3 1 5.75 6 6.25 
 8 1.5 2.75 1.5 6 5.5 6 
 9 1 3.25 0.75 5.5 6.25 6 
 10 1.25 3 1.5 5.25 5.5 6.5 
 11 1.5 3 0.75 5.5 5.75 6 
 12 2.5 3.75 1.5 5.75 5.5 5.75 
 13 3.75 4 1 5.75 6 5.5 
 14 4.25 2.25 0 6.5 5.25 5 
 15 3.5 3 0.5 6.25 6 5.75 
 Avg 16 2.533333 3.233333 1.316667 5.833333 6 6.066667 
        
 d moved 7.066667 5.766667 4.433333 1.316667 2.55 1.333333 
 %space 0.263889 0.359259 0.228986 0.815851 0.701754 0.81982 
 %moved 0.736111 0.640741 0.771014 0.184149 0.298246 0.18018 
 Avg %  0.715955   0.220858  
 Std dev  0.067435   0.067049  
 
  
 32 
HCT116 -/- 8-13-09 
HCT -/-  Control Wells  MTOB Treated 
Wells 
 
81309  C1 C2 C3 M1 M2 M3 
 0 1.875 2 1.625 2 1.75 1.75 
 0 2.25 1.75 1.5 1.5 2 1.875 
 0 1.625 1.875 1.625 1.625 2 1.625 
 0 1.875 1.75 1.625 1.75 1.75 1.875 
 0 1.625 2 1.875 1.75 1.875 1.75 
 Avg 0 1.85 1.875 1.65 1.725 1.875 1.775 
 1 1.375 1.375 1 1.25 1.75 1.5 
 2 1.25 1.25 1.125 1.25 1.375 1.75 
 3 1.25 1 1.125 1.25 1.5 1.5 
 4 1.375 1.25 1.125 1.375 1.375 1.625 
 5 1.125 1.125 1.25 1.375 1.25 1.25 
 6 1.25 1.375 1.125 1.5 1.5 1.375 
 7 1.375 1.375 1.25 1.125 1.375 1.5 
 8 1.375 1.25 1.125 1.375 1.5 1.75 
 9 1 1.375 0.875 1 1.5 1.375 
 10 1.125 1 1 1.375 1.25 1.5 
 11 1.375 1.25 1 1.25 1.5 1.5 
 12 1 1.25 1 1.5 1.625 1.125 
 13 1.25 1.125 1.125 1.25 1.25 1.375 
 14 1.25 1.25 1.25 1.375 1.25 1.375 
 15 1.25 0.75 1.25 1.25 1.375 1 
 Avg 16 1.241667 1.2 1.108333 1.3 1.425 1.433333 
 D 
moved 
0.608333 0.675 0.541667 0.425 0.45 0.341667 
 % 
space 
0.671171 0.64 0.671717 0.753623 0.76 0.807512 
 % 
moved 
0.328829 0.36 0.328283 0.246377 0.24 0.192488 
 Avg %  0.339037   0.226288  
 Std Dev  0.018156   0.029445  
 
  
 33 
HCT116 -/- 8-21-09 
HCT -/-   Control   MTOB  
82109  C1 C2 C3 M1 M2 M3 
 1 7.5 7.75 7.5 8.5 10.5 8.75 
 2 10 8.25 6.75 9 10.75 9 
 3 9.5 9.25 7 9.25 10.25 8.5 
 4 9.5 8.5 7.5 8.75 10 9 
 5 9.25 9.5 7.75 9.25 10.5 8.5 
 Avg 0 9.15 8.65 7.3 8.95 10.4 8.75 
        
 1 7.75 8 6.25 8.75 10 9.5 
 2 8 7 6.75 8.75 9.5 8.75 
 3 7.5 7.25 6.25 9 9.5 8.75 
 4 7.5 7.5 7 8.75 9 8.25 
 5 7.25 8 6.75 8.25 9.25 8 
 6 7.25 7 6.5 8 9 8.75 
 7 8 8.25 6.5 8.5 9.25 8.75 
 8 7 8.5 6 8 9.25 8.25 
 9 8 8 6.25 8 9.75 7.5 
 10 7 7.25 6.5 7.75 9.25 7 
 11 8.5 6.75 6.5 8.5 10 8 
 12 7.5 7.5 6.25 8.25 10 7.5 
 13 8.25 7.75 5.75 8.25 9.5 7.75 
 14 8 7.25 6 8.5 10 8.5 
 15 7.25 7.25 6.75 7.5 10 8.25 
 Avg 8 7.65 7.55 6.4 8.316667 9.55 8.233333 
        
 d moved 1.5 1.1 0.9 0.633333 0.85 0.516667 
 %space 0.836066 0.872832 0.876712 0.929236 0.918269 0.940952 
 %moved 0.163934 0.127168 0.123288 0.070764 0.081731 0.059048 
 Avg %  0.13813   0.070514  
 Std dev  0.022431   0.011344  
 
  
 34 
HCT116 -/- 8-31-09 
HCT -/-   Control   MTOB  
83109  C1 C2 C3 M1 M2 M3 
 1 2 1.75 2 2 1.75 2 
 2 2.25 1.875 1.625 2.125 1.875 2 
 3 1.625 2 1.875 1.875 1.625 1.875 
 4 1.875 1.875 1.625 1.875 1.75 2 
 5 1.875 2 2 1.625 1.875 1.75 
 Avg 0 1.925 1.9 1.825 1.9 1.775 1.925 
        
 1 1.5 1.5 1.125 1.375 1.25 1.625 
 2 1.375 1.375 1.25 1.375 1.5 1.875 
 3 1.375 1.125 1.25 1.375 1.625 1.625 
 4 1.5 1.375 1.25 1.5 1.5 1.75 
 5 1.25 1.25 1.375 1.5 1.375 1.375 
 6 1.375 1.5 1.25 1.625 1.625 1.5 
 7 1.5 1.5 1.375 1.25 1.5 1.625 
 8 1.25 1.125 1 1.25 1.375 1.625 
 9 0.875 1.25 1 1.625 1.375 1.25 
 10 1 0.875 0.875 1.25 1.125 1.375 
 11 1.25 1.125 0.875 1.125 1.375 1.375 
 12 0.875 1.125 0.875 1.375 1 1 
 13 1.125 1 1 1.125 1.125 1.25 
 14 1.125 1.125 1.125 1.25 1.125 1.25 
 15 1.125 0.625 1.125 1.125 1.25 1.25 
 Avg 16 1.233333 1.191667 1.116667 1.341667 1.341667 1.45 
        
 d moved 0.691667 0.708333 0.708333 0.558333 0.433333 0.475 
 %space 0.640693 0.627193 0.611872 0.70614 0.755869 0.753247 
 %moved 0.359307 0.372807 0.388128 0.29386 0.244131 0.246753 
 Avg %  0.373414   0.261581  
 Std dev  0.01442   0.027984  
 
  
 35 
HCT -/-   Control   MTOB  
83109  C1 C2 C3 M1 M2 M3 
 1 1.875 1.625 1.875 1.875 1.625 1.875 
 2 2.125 1.75 1.5 2 1.75 1.875 
 3 1.75 1.875 1.75 1.75 1.75 1.75 
 4 2 2 1.75 2 1.875 2.125 
 5 2 1.875 2 1.75 2 1.875 
 Avg 0 1.95 1.825 1.775 1.875 1.8 1.9 
        
 1 1.625 1.625 1.25 1.5 1.375 1.75 
 2 1.25 1.25 1.125 1.625 1.375 1.75 
 3 1.5 1.25 1.375 1.5 1.75 1.75 
 4 1.375 1.25 1.125 1.375 1.375 1.625 
 5 1.375 1.375 1.5 1.625 1.5 1.5 
 6 1.25 1.375 1.125 1.5 1.5 1.375 
 7 1.625 1.375 1.5 1.375 1.625 1.75 
 8 1.125 1 1 1.5 1.25 1.5 
 9 1 1.375 1.125 1.75 1.5 1.375 
 10 1 1 1 1.125 1 1.25 
 11 1.375 1.25 1 1.25 1.5 1.5 
 12 1 1 0.75 1.25 1.125 0.875 
 13 1.25 1.125 1.125 1.25 1.25 1.375 
 14 1 1 1 1.125 1 1.125 
 15 1.25 1 1.25 1.25 1.375 1.375 
 Avg 16 1.266667 1.216667 1.15 1.4 1.366667 1.458333 
        
 d moved 0.683333 0.608333 0.625 0.475 0.433333 0.441667 
 %space 0.649573 0.666667 0.647887 0.746667 0.759259 0.767544 
 %moved 0.350427 0.333333 0.352113 0.253333 0.240741 0.232456 
 Avg %  0.345291   0.242177  
 Std dev  0.01039   0.010512  
 
  
 36 
MCF7 8-14-09 
MCF7   Control   MTOB  
81409  C1 C2 C3 M1 M2 M3 
 0 1.75 2 1.625 2.25 1.875 1.625 
 0 1.625 1.875 1.5 2.125 1.75 1.625 
 0 2 1.625 1.875 2 1.875 1.75 
 0 1.875 1.875 1.5 2.125 1.875 1.5 
 0 1.875 2 1.75 2 1.75 1.625 
 Avg 0 1.825 1.875 1.65 2.1 1.825 1.625 
 1 1.25 1.75 1.25 1.75 1.75 1.5 
 2 1.5 1.625 1.375 1.625 2 2 
 3 1.625 1.25 1.375 1.875 1.75 1.625 
 4 1.75 1.5 1.125 1.75 1.875 1.5 
 5 1.5 1.375 1.5 1.625 1.625 1.5 
 6 1.375 1.25 1 1.875 1.875 1.625 
 7 1.25 1.5 1.25 1.875 1.625 1.5 
 8 1.5 1.5 1 1.75 1.625 1.375 
 9 1.625 1.625 1.5 1.75 1.5 1.25 
 10 1.375 1.375 1.25 1.75 1.5 1.5 
 11 1.375 1.75 1.375 1.625 1.5 1.25 
 12 1.5 1.5 1 1.625 1.5 1.25 
 13 1.25 1.75 1.375 1.5 1.375 1.375 
 14 1.5 1.375 1.25 1.625 1.375 1.25 
 15 1.375 1.5 1.25 1.625 1.25 1.25 
 Avg 16 1.45 1.508333 1.258333 1.708333 1.608333 1.45 
 Distance 0.375 0.366667 0.391667 0.391667 0.216667 0.175 
 %space 0.794521 0.804444 0.762626 0.813492 0.881279 0.892308 
 %moved 0.205479 0.195556 0.237374 0.186508 0.118721 0.107692 
 Avg %  0.212803   0.137641  
 Std Dev  0.02185   0.042678  
 
  
 37 
MCF7 8-26-09 
MCF7   Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
8hr 1 8.5 9.25 9.5 9.5 8.5 12.25 
 2 8.75 9 9.75 9.75 8.5 12.25 
 3 8.75 8.75 8.5 10 8 12.5 
 4 8.5 9 9.25 9.25 8.25 12.25 
 5 9 8.75 9 9.75 7.75 12.25 
 Avg 0 8.7 8.95 9.2 9.65 8.2 12.3 
        
 1 4.5 6.75 6.5 9.75 8.25 10.5 
 2 4.75 6.75 6 9.5 7.75 10.25 
 3 4.5 6.5 5.75 9.5 7.75 10.75 
 4 4.5 6.25 6 9.25 7.5 11.25 
 5 4.75 6.75 6.25 9 8.25 11 
 6 5 6 6.25 9 7.75 11 
 7 5.25 6 6.25 9.5 8 10.75 
 8 5.25 6.75 5.75 9.25 7.5 10.75 
 9 5.25 6.75 6.25 9.25 7.25 10.25 
 10 4.5 6.5 6.5 9 7.25 11 
 11 4.75 6.5 6.5 9.25 7 11.5 
 12 5.5 5.75 6.5 8.75 7.25 11.5 
 13 5.25 5.75 6.5 9.25 7 10.75 
 14 5 5.5 6.25 9 7.5 10.5 
 15 5.5 5.5 6 9.5 7.25 10 
 Avg 8 4.95 6.266667 6.216667 9.25 7.55 10.78333 
        
 d moved 3.75 2.683333 2.983333 0.4 0.65 1.516667 
 %space 0.568966 0.700186 0.675725 0.958549 0.920732 0.876694 
 %moved 0.431034 0.299814 0.324275 0.041451 0.079268 0.123306 
 Avg %  0.351708   0.081342  
 Std dev  0.069779   0.040967  
 
  
 38 
MCF7   Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
8hr b 1 8 8.5 7.75 11.25 10.25 7 
 2 8.25 8.25 8 12 10.5 7.25 
 3 8.5 8 7.75 11.75 10 6.75 
 4 8 8 7.5 12 11 6.75 
 5 8.25 8.5 8 12 10.25 7.5 
 Avg 0 8.2 8.25 7.8 11.8 10.4 7.05 
        
 1 7 8 7 11.5 8 6 
 2 7.25 7.5 6.5 11 8.25 5.75 
 3 6.75 7 7 10 8 6.5 
 4 6 7 6.5 10.25 8.5 6.25 
 5 6.75 6.75 6.75 10.5 8.5 6.5 
 6 5.75 6.5 6.25 11 8 5.75 
 7 6.25 6.75 6.5 10 7.75 6.5 
 8 7 6.25 6.25 9.5 8.5 6.25 
 9 7 6.5 6.25 9.5 8.25 5.5 
 10 6.5 7.25 5.75 10 8.75 5.75 
 11 6.25 7.25 5.5 9.75 9.25 5.75 
 12 7 6.75 6 10.25 8.75 6 
 13 6.75 6.5 6 10 8.5 6 
 14 7 6.25 5.75 9.5 8 6.5 
 15 7.5 6.25 6 9.5 7.75 6 
 Avg 8 6.716667 6.833333 6.266667 10.15 8.316667 6.066667 
        
 d moved 1.483333 1.416667 1.533333 1.65 2.083333 0.983333 
 %space 0.819106 0.828283 0.803419 0.860169 0.799679 0.86052 
 %moved 0.180894 0.171717 0.196581 0.139831 0.200321 0.13948 
 Avg %  0.183064   0.159877  
 Std dev  0.012573   0.035026  
 
  
 39 
MCF7   Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
16 hr 1 6.75 9 9.25 9.25 9.5 8.5 
 2 8.25 8.75 9.5 10 9.5 8 
 3 7.75 9.25 9 10 9.25 8.25 
 4 8 8.5 9.25 10.25 9.75 8.75 
 5 7.25 9 9 9.25 9 8.5 
 Avg 0 7.6 8.9 9.2 9.75 9.4 8.4 
        
 1 5.25 5.75 5.5 7.5 7.5 7 
 2 5.25 6 5.75 7.5 7 6.75 
 3 5.75 6 4.75 8 7.25 6.75 
 4 5.75 5.75 5.5 7.75 8 6.25 
 5 5.25 6 5.5 6.75 7.5 6.25 
 6 5.25 5.5 5.5 7.5 8 6.5 
 7 4.75 6.25 4.75 6.75 8.25 6 
 8 5 6.5 4.75 6.25 7 6 
 9 4.75 6.25 5 6.5 7.5 6.25 
 10 5.75 6 5.25 6.5 7.5 5.75 
 11 5.5 5.5 5 7.25 7 6 
 12 5.25 5.25 5 6.5 7.75 6.25 
 13 5 5.75 4.5 7.25 7 6 
 14 5 5.5 4.75 7.25 7.25 6.5 
 15 5 5.75 4.75 7.5 7.5 6.25 
 Avg 16 5.233333 5.85 5.083333 7.116667 7.466667 6.3 
        
 d moved 2.366667 3.05 4.116667 2.633333 1.933333 2.1 
 %space 0.688596 0.657303 0.552536 0.729915 0.794326 0.75 
 %moved 0.311404 0.342697 0.447464 0.270085 0.205674 0.25 
 Avg %  0.367188   0.24192  
 Std dev  0.07126   0.032957  
 
  
 40 
MCF7   Control   MTOB  
82609  C1 C2 C3 M1 M2 M3 
16hr b 1 10.5 10 8.75 9.75 9.5 10.5 
 2 10.25 9.5 8.5 9.5 10.25 11 
 3 10 9.25 9 9.25 9.5 11 
 4 10 9.5 8.75 9.75 9.75 10.5 
 5 9.75 9.75 8.5 10 9.5 10.25 
 Avg 0 10.1 9.6 8.7 9.65 9.7 10.65 
        
 1 7 5.5 5 7.75 7 8 
 2 6.5 5.75 5.5 8 7.5 7.75 
 3 6.75 6 4.75 8 7.75 7.5 
 4 6.5 6.25 5.25 7.5 8.25 8 
 5 6.25 6.25 6 7 8 7.5 
 6 6.75 6.5 6 7.25 7.5 7.75 
 7 6.25 6.5 5 6.75 7.25 7 
 8 6 7 4.75 6 7 7.5 
 9 6.5 6 5.25 6.5 7 6.5 
 10 6 6 4.75 6.5 7.5 6.75 
 11 6.5 6.75 5.25 7.25 6 6 
 12 6.25 6.25 5.75 6.75 7.5 6.75 
 13 7 7 5.5 6.5 7 6.5 
 14 6.75 6.5 5 6.5 7 7 
 15 6.25 6.5 5.25 6.25 8 7.75 
 Avg 16 6.483333 6.316667 5.266667 6.966667 7.35 7.216667 
        
 d moved 3.616667 3.283333 3.433333 2.683333 2.35 3.433333 
 %space 0.641914 0.657986 0.605364 0.721934 0.757732 0.677621 
 %moved 0.358086 0.342014 0.394636 0.278066 0.242268 0.322379 
 Avg %  0.364912   0.280904  
 Std dev  0.026967   0.040131  
 
 
